Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976247 | 0.79 | P2RX3 (0.38) | ADORA2AADORA1KDM4ERXFP1P2RX3 | |
| SCHEMBL15434635 | 0.78 | CSNK1A1 (0.39) | ADORA2AADORA1CSNK1A1CLK4MBOAT4 | |
| SCHEMBL263835 | 0.78 | CSNK1A1 (0.64) | ADORA2AADORA1CSNK1A1CLK4KDM4E | |
| SCHEMBL14757551 | 0.75 | ADORA2A (0.51) | ADORA2AADORA1CSNK1A1CLK4KDM4E | |
| SCHEMBL3356613 | 0.75 | CSNK1A1 (0.55) | ADORA2AADORA1CSNK1A1CLK4P2RX3 | |
| SCHEMBL24135156 | 0.75 | CSNK1A1 (0.60) | ADORA2AADORA1CSNK1A1CLK4MBOAT4 | |
| SCHEMBL28110085 | 0.75 | CSNK1A1 (0.37) | ADORA2AADORA1CSNK1A1CLK4MBOAT4 | |
| SCHEMBL20168096 | 0.75 | CSNK1A1 (0.37) | ADORA2AADORA1CSNK1A1CLK4MBOAT4 | |
| SCHEMBL18874068 | 0.75 | ADORA2A (0.47) | ADORA2AADORA1CSNK1A1CLK4KDM4E | |
| SCHEMBL2872655 | 0.75 | ADORA2A (0.47) | ADORA2AADORA1CSNK1A1CLK4MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015106012-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-16 | — | — | WO | claimed |
| EP-4638445-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024137727-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20130225816-A1 | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053561-A1 | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (US) | 2013-02-28 | — | — | US | disclosed |
| US-8309720-B2 | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-13 | — | — | US | disclosed |
| WO-2012071511-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| CN-102137672-A | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV | 2011-07-27 | — | — | CN | disclosed |
| EP-2310012-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2011-04-20 | — | — | EP | disclosed |
| US-20100004450-A1 | Process for the preparation of substituted pyrimidine derivatives | CESCO-CANCIAN SERGIO | 2010-01-07 | — | — | US | disclosed |
| WO-2010002774-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | ADORA2A 1449/4885ADORA1 976/4885CSNK1A1 31/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADORA2A 1165/4885ADORA1 2514/4885CSNK1A1 307/4885 |
| US-20100004450-A1 | Process for the preparation of substituted pyrimidine derivatives | HRH4, HRH2, HRH3 | ADORA2A 43/4885ADORA1 42/4885CSNK1A1 3800/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | ADORA2A 1835/4885ADORA1 2297/4885CSNK1A1 1872/4885 |
| US-20130053561-A1 | Process for the preparation of substituted pyrimidine derivatives | HRH4, HRH2, HRH3 | ADORA2A 43/4885ADORA1 42/4885CSNK1A1 3800/4885 |
| US-20130225816-A1 | Process for the preparation of substituted pyrimidine derivatives | HRH4, HRH2, HRH3 | ADORA2A 43/4885ADORA1 42/4885CSNK1A1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.